BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 12592346)

  • 1. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
    Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
    Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
    Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
    Shi Y; Wu J; Mick R; Cerniglia GJ; Cohen-Jonathan E; Rhim JS; Koch CJ; Bernhard EJ
    Prostate; 2005 Jan; 62(1):69-82. PubMed ID: 15389805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.
    Lau CP; Huang L; Tsui SK; Ng PK; Leung PY; Kumta SM
    J Orthop Res; 2011 Mar; 29(3):403-13. PubMed ID: 20886653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
    Nørgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ; Poulsen HS; Moses HL
    Clin Cancer Res; 1999 Jan; 5(1):35-42. PubMed ID: 9918200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
    Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
    Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
    Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
    Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
    Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J; Bizouarn FA; Chen Z; Ohkanda J; Hamilton AD; Munoz-Antonia T; Sebti SM
    Oncogene; 2000 Nov; 19(48):5525-33. PubMed ID: 11114730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
    Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
    Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
    Sepp-Lorenzino L; Rosen N
    J Biol Chem; 1998 Aug; 273(32):20243-51. PubMed ID: 9685373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.